EGFR and glioblastoma: Depatuxizumab mafodotin (ABT-414), which consists of an EGFR-specific humanized antibody, a non-cleavable malemidocaproyl linker, and monomethyl auristatin F, was tested for patients with EGFR-amplified newly diagnosed glioblastoma but discontinued due to a lack of survival benefit (50).